This regulatory mechanism differs from the conventional pyruvate dehydrogenase (PDH)-PDK axis, suggesting that FAHD1, as a crucial regulator of tumor metabolic reprogramming, may serve as a potential target for cancer therapy and metabolic interventions. The gene discussed is PDP1; the disease is neoplasm.